1
|
Busch J, Kaplan J, Merk T, Köhler R, Neumann W, Kühn A. P 43 Optimizing beta-burst driven adaptive deep brain stimulation for Parkinson's disease. Clin Neurophysiol 2022. [DOI: 10.1016/j.clinph.2022.01.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Grushko M, Goldstein J, ElSeht Z, Alarcon A, Jones N, Samizadeh M, Zhu Y, Kaplan J, Arline K. 1146P Closing the target gap: A computational approach to optimizing therapeutic selection for cancer patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
3
|
Moreno-Artero E, Morice-Picard F, Bremond-Gignac D, Drumare-Bouvet I, Duncombe-Poulet C, Leclerc-Mercier S, Dufresne H, Kaplan J, Jouanne B, Arveiler B, Taieb A, Hadj-Rabia S. Management of albinism: French guidelines for diagnosis and care. J Eur Acad Dermatol Venereol 2021; 35:1449-1459. [PMID: 34042219 DOI: 10.1111/jdv.17275] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Accepted: 03/22/2021] [Indexed: 12/12/2022]
Abstract
Albinism is a worldwide genetic disorder caused by mutations in at least 20 genes, identified to date, that affect melanin production or transport in the skin, hair and eyes. Patients present with variable degrees of diffuse muco-cutaneous and adnexal hypopigmentation, as well as ocular features including nystagmus, misrouting of optic nerves and foveal hypoplasia. Less often, albinism is associated with blood, immunological, pulmonary, digestive and/or neurological anomalies. Clinical and molecular characterizations are essential in preventing potential complications. Disease-causing mutations remain unknown for about 25% of patients with albinism. These guidelines have been developed for the diagnosis and management of syndromic and non-syndromic forms of albinism, based on a systematic review of the scientific literature. These guidelines comprise clinical and molecular characterization, diagnosis, therapeutic approach and management.
Collapse
Affiliation(s)
- E Moreno-Artero
- Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France
| | - F Morice-Picard
- Pediatric Dermatology Unit, National Centre for Rare Skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| | - D Bremond-Gignac
- Department of Ophthalmology, Reference Centre for Rare Ocular Diseases (OPHTARA), Hôpital Necker-Enfants Malades, APHP5, Paris, France.,Université de Paris-Centre, Paris, France
| | - I Drumare-Bouvet
- Service d'exploration de la vision et neuro-ophtalmologie, CHRU de Lille, Lille, France
| | | | - S Leclerc-Mercier
- Department of Pathology, Hôpital Necker-Enfants Malades, APHP5, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris-Centre, Paris, France
| | - H Dufresne
- Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France.,Service Social Pédiatrique, Hôpital Necker-Enfants Malades, APHP5, Université de Paris-Centre, Paris, France
| | - J Kaplan
- Laboratory of Genetics in Ophthalmology, Imagine Institute, Paris, France
| | - B Jouanne
- French Association for Albinism (Genespoir), Rennes, France
| | - B Arveiler
- Molecular Genetics Laboratory, CHU de Bordeaux, Bordeaux, France.,INSERM U1211, Maladies Rares, Génétique et Métabolisme, Bordeaux, France
| | - A Taieb
- Pediatric Dermatology Unit, National Centre for Rare Skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| | - S Hadj-Rabia
- Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France.,Université de Paris-Centre, Paris, France
| |
Collapse
|
4
|
Kaplan J, Gero A, Simmons R, Kaiser J, Fay K, Turok D. P82 Feasibility of randomization to the copper or levonorgestrel IUD. Contraception 2020. [DOI: 10.1016/j.contraception.2020.07.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Rotenberg O, Fridman D, Doulaveris G, Renz M, Kaplan J, Gebb J, Xie X, Goldberg GL, Dar P. Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling. Ultrasound Obstet Gynecol 2020; 55:546-551. [PMID: 31389091 DOI: 10.1002/uog.20421] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 07/15/2019] [Accepted: 07/26/2019] [Indexed: 06/10/2023]
Abstract
OBJECTIVE To assess the long-term outcome of postmenopausal women diagnosed with non-atypical endometrial hyperplasia (NEH). METHODS This was a retrospective study of women aged 55 or older who underwent endometrial sampling in our academic medical center between 1997 and 2008. Women who had a current or recent (< 2 years) histological diagnosis of NEH were included in the study group and were compared with those diagnosed with atrophic endometrium (AE). Outcome data were obtained until February 2018. The main outcomes were risk of progression to endometrial carcinoma and risk of persistence, recurrence or new development of endometrial hyperplasia (EH) ('persistent EH'). Logistic regression analysis was used to identify covariates that were independent risk factors for progression to endometrial cancer or persistent EH. RESULTS During the study period, 1808 women aged 55 or older underwent endometrial sampling. The median surveillance time was 10.0 years. Seventy-two women were found to have a current or recent diagnosis of NEH and were compared with 722 women with AE. When compared to women with AE, women with NEH had significantly higher body mass index (33.9 kg/m2 vs 30.6 kg/m2 ; P = 0.01), greater endometrial thickness (10.00 mm vs 6.00 mm; P = 0.01) and higher rates of progression to type-1 endometrial cancer (8.3% vs 0.8%; P = 0.0003) and persistent NEH (22.2% vs 0.7%; P < 0.0001). They also had a higher rate of progression to any type of uterine cancer or persistent EH (33.3% vs 3.5%; P < 0.0001). Women with NEH had a significantly higher rate of future surgical intervention (51.4% vs 15.8%; P < 0.0001), including future hysterectomy (34.7% vs 9.8%; P < 0.0001). On multivariable logistic regression analysis, only NEH remained a significant risk factor for progression to endometrial cancer or persistence of EH. CONCLUSIONS Postmenopausal women with NEH are at significant risk for persistent EH and progression to endometrial cancer, at rates higher than those reported previously. Guidelines for the appropriate management of postmenopausal women with NEH are needed in order to decrease the rate of persistent disease or progression to cancer. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- O Rotenberg
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - D Fridman
- Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
| | - G Doulaveris
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - M Renz
- Department of Obstetrics and Gynecology, Gynecologic Oncology, Stanford University, Stanford, CA, USA
| | - J Kaplan
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - J Gebb
- Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA
| | - X Xie
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - G L Goldberg
- Department of Obstetrics and Gynecology, Gynecologic Oncology, Northwell Health, LIJ Medical Center, New Hyde Park, New York, NY, USA
| | - P Dar
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| |
Collapse
|
6
|
Plaisancié J, Tarilonte M, Ramos P, Jeanton-Scaramouche C, Gaston V, Dollfus H, Aguilera D, Kaplan J, Fares-Taie L, Blanco-Kelly F, Villaverde C, Francannet C, Goldenberg A, Arroyo I, Rozet JM, Ayuso C, Chassaing N, Calvas P, Corton M. Implication of non-coding PAX6 mutations in aniridia. Hum Genet 2018; 137:831-846. [PMID: 30291432 DOI: 10.1007/s00439-018-1940-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 09/23/2018] [Indexed: 01/14/2023]
Abstract
There is an increasing implication of non-coding regions in pathological processes of genetic origin. This is partly due to the emergence of sophisticated techniques that have transformed research into gene expression by allowing a more global understanding of the genome, both at the genomic, epigenomic and chromatin levels. Here, we implemented the analysis of PAX6, whose coding loss-of-function variants are mainly implied in aniridia, by studying its non-coding regions (untranslated regions, introns and cis-regulatory sequences). In particular, we have taken advantage of the development of high-throughput approaches to screen the upstream and downstream regulatory regions of PAX6 in 47 aniridia patients without identified mutation in the coding sequence. This was made possible through the use of custom targeted resequencing and/or CGH array to analyze the entire PAX6 locus on 11p13. We found candidate variants in 30 of the 47 patients. 9/30 correspond to the well-known described 3' deletions encompassing SIMO and other enhancer elements. In addition, we identified numerous different variants in various non-coding regions, in particular untranslated regions. Among these latter, most of them demonstrated an in vitro functional effect using a minigene strategy, and 12/21 are thus considered as causative mutations or very likely to explain the phenotypes. This new analysis strategy brings molecular diagnosis to more than 90% of our aniridia patients. This study revealed an outstanding mutation pattern in non-coding PAX6 regions confirming that PAX6 remains the major gene for aniridia.
Collapse
Affiliation(s)
- Julie Plaisancié
- Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan, CHU Toulouse, Place du Dr Baylac, 31059, Toulouse Cedex 9, France.
- INSERM U1056, Université Toulouse III, Toulouse, France.
| | - M Tarilonte
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - P Ramos
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - C Jeanton-Scaramouche
- Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan, CHU Toulouse, Place du Dr Baylac, 31059, Toulouse Cedex 9, France
| | - V Gaston
- Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan, CHU Toulouse, Place du Dr Baylac, 31059, Toulouse Cedex 9, France
| | - H Dollfus
- Centre de Référence pour les affections rares en génétique ophtalmologique, CARGO, Filière SENSGENE, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - D Aguilera
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - J Kaplan
- Laboratoire de Génétique Ophtalmologique INSERM U1163, Institut Imagine, Paris, France
| | - L Fares-Taie
- Laboratoire de Génétique Ophtalmologique INSERM U1163, Institut Imagine, Paris, France
| | - F Blanco-Kelly
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - C Villaverde
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - C Francannet
- Service de Génétique Médicale, CHU Estaing, Clermont-Ferrand, France
| | - A Goldenberg
- Service de Génétique, CHU de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - I Arroyo
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
- Department of Genetics, Hospital of Cáceres, Cáceres, Spain
| | - J M Rozet
- Laboratoire de Génétique Ophtalmologique INSERM U1163, Institut Imagine, Paris, France
| | - C Ayuso
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - N Chassaing
- Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan, CHU Toulouse, Place du Dr Baylac, 31059, Toulouse Cedex 9, France
- INSERM U1056, Université Toulouse III, Toulouse, France
| | - P Calvas
- Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan, CHU Toulouse, Place du Dr Baylac, 31059, Toulouse Cedex 9, France
- INSERM U1056, Université Toulouse III, Toulouse, France
| | - M Corton
- Department of Genetics, Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz University Hospital-Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| |
Collapse
|
7
|
Plaisancié J, Ragge N, Dollfus H, Kaplan J, Lehalle D, Francannet C, Morin G, Colineaux H, Calvas P, Chassaing N. FOXE3
mutations: genotype-phenotype correlations. Clin Genet 2018; 93:837-845. [DOI: 10.1111/cge.13177] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2017] [Revised: 08/21/2017] [Accepted: 08/22/2017] [Indexed: 01/25/2023]
Affiliation(s)
- J. Plaisancié
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse; Toulouse France
- INSERM U1056; Université Toulouse III; Toulouse France
| | - N.K. Ragge
- Faculty of Health and Life Sciences; Oxford Brookes University; Oxford UK
- West Midlands Regional Genetics Service; Birmingham Women and Children’s NHS Foundation Trust; Birmingham UK
| | - H. Dollfus
- Centre de Référence pour les affections rares en génétique ophtalmologique; CARGO, Filière SENSGENE, Hôpitaux Universitaires de Strasbourg; Strasbourg France
| | - J. Kaplan
- INSERM U1163; Génétique Ophtalmologique; Paris France
| | - D. Lehalle
- Centre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs; Hôpital d'Enfants; Dijon France
| | - C. Francannet
- Service de Génétique Médicale; CHU Estaing; Clermont-Ferrand France
| | - G. Morin
- Service de génétique; Hôpital nord d’Amiens; Amiens France
| | - H. Colineaux
- Department of Epidemiology, Health Economics and Public Health; Toulouse University Hospital; France
- LEASP UMR1027, INSERM; Université Toulouse III; Toulouse France
| | - P. Calvas
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse; Toulouse France
- INSERM U1056; Université Toulouse III; Toulouse France
| | - N. Chassaing
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse; Toulouse France
- INSERM U1056; Université Toulouse III; Toulouse France
| |
Collapse
|
8
|
Souied EH, Rozet JM, Gerber S, Dufier JL, Soubrane G, Coscas G, Munnich A, Kaplan J. Two Novel Missense Mutations in the Peripherin/RDS Gene in two Unrelated French Patients with Autosomal Dominant Retinitis Pigmentosa. Eur J Ophthalmol 2018; 8:98-101. [PMID: 9673478 DOI: 10.1177/112067219800800208] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To report the identification of two novel RDS mutations in the peripherin/RDS gene of two unrelated French patients affected by autosomal dominant retinitis pigmentosa (ADRP). Methods Fifty-eight unrelated patients affected by ADRP were analyzed. Our diagnostic criteria for RP were bilateral fundus involvement, concentric depression of the visual field and severe involvement on electroretinogram. Transmission of the trait was unambiguous. Our strategy was to analyze the coding sequence of the gene using a combination of single-strand conformation polymorphism (SSCP) and direct sequence analysis of the exons of the gene. Exons that displayed conformational polymorphisms were sequenced on an automated DNA sequencer. Results The sequence analyses revealed two previously unreported missense mutations: Cys165Tyr and Phe211Leu in exons 1 and 2, respectively. None of the 70 controls analyzed carried these base changes. Cosegregation of the base substitution with the disease could be tested in both families presenting the Cys165Tyr and Phe211Leu mutations. Conclusions Several lines of evidence support the idea that these base substitutions are disease-causing mutations. To the best of our knowledge, no peripherin/RDS gene analysis has been previously reported in ADRP in France.
Collapse
Affiliation(s)
- E H Souied
- Service de Génétique I'Enfant INSERM-U-393 Hôpital des Enfants-Malades, Paris
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Malca N, Serror K, Mimoun M, Chatelain S, Kaplan J, Chaouat M, Marco O, Boccara D. Our 35 years' experience on postburn heterotopic ossification: A three-step treatment. ANN CHIR PLAST ESTH 2018; 63:316-322. [PMID: 29289387 DOI: 10.1016/j.anplas.2017.11.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Accepted: 11/30/2017] [Indexed: 11/18/2022]
Abstract
Our retrospective study of burn patients presents a three-step treatment of heterotopic ossification: excision surgery, early rehabilitation, and analgesia. We included patients admitted to the department for treatment of postburn heterotopic ossification between January 1, 1979, and September 30, 2015. The mean age at the time of the burn was 43.3 years. Men accounted for the majority of burn patients who developed an osteoma (70.8%). The mean total skin area burned was 38.4%. No osteoma justifying surgery was found for any patient with a total burned skin area less than 19%. The burned zones were related to the osteoma development in 94.3% of cases. On average, the surgery took place 10.8 months after the burn. The osteotomy was accompanied by surgical treatment of a contracture in 37.1% of patients. Most of the osteomata were found at the elbows (30), followed by the shoulders (3), and finally the knees (2). Rehabilitation began on D0 after the surgery, except if a flap or a thin-skin graft was used. Regarding analgesia, opiates were prescribed systematically during the immediate postoperative period. Elbow range of motion on flexion improved by a mean of 84.1°. During the postoperative period, we found 2 recurrences of osteoma and 1 elbow hematoma in two separate patients. There were no postoperative infections or neurological sequelae. Our retrospective French study confirmed results found in the international literature. The three-step treatment - excision surgery, early rehabilitation, and antalgia - seems to be the best means of treating osteoma with satisfactory results. Surgery is indicated only in the case of functional impairment and not simply based on imaging.
Collapse
Affiliation(s)
- N Malca
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - K Serror
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - M Mimoun
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - S Chatelain
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J Kaplan
- NewYork-Presbyterian hospital, Columbia university medical center, New York, USA
| | - M Chaouat
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - O Marco
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - D Boccara
- Department of plastic surgery, Burn center (centre de traitement des brûlés), hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| |
Collapse
|
10
|
Luca R, Rizzo M, Mando P, Perez de La Puente C, Blanco A, Rivero S, Lutter G, Cappuccio F, Amat M, Kaplan J, Chacon R, Chacon M. Independent prognostic impact of lympho-vascular invasion in cutaneous melanoma patients with sentinel lymph node biopsy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Kaplan J, Gordon L, Infante J, Popat R, Rambaldi A, Madan S, Patel M, Gritti G, El-Sharkawi D, Chau I, Radford J, Perez De Oteyza J, Zinzani P, Iyer S, Faucette S, Sheldon-Waniga E, Stumpo K, Shou Y, Carpio C, Bosch F. TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_60] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Kaplan
- Department of Medicine; Northwestern University; Chicago USA
| | - L. Gordon
- Robert H Lurie Comprehensive Cancer Center; Northwestern University Feinberg School of Medicine; Chicago USA
| | - J. Infante
- Drug Development Unit; Sarah Cannon Research Institute/Tennessee Oncology; Nashville USA
| | - R. Popat
- NIHR Clinical Research Facility; UCLH; London UK
| | - A. Rambaldi
- Dipartimento di Oncologia ed Emato-Oncologia / Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano / Ospedale Papa Giovanni XXII; Bergamo Italy
| | - S. Madan
- Dipartimento di Oncologia ed Emato-Oncologia/Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano/Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - M.R. Patel
- Hematology-Oncology; Florida Cancer Specialists/Sarah Cannon Research Institute; Sarasota USA
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - D. El-Sharkawi
- Haematology; NIHR UCLH Clinical Research Facility; London UK
| | - I. Chau
- Department of Medicine; Royal Marsden Hospital; Surrey UK
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | | | - P. Zinzani
- Hematology, Institute of Hematology “Seragnoli”; University of Bologna; Bologna Italy
| | - S. Iyer
- Advanced Therapeutics, Institute of Academic Medicine; Houston Methodist Cancer Center; Houston USA
| | - S. Faucette
- Clinical Pharmacology; Takeda Pharmaceuticals International Co.; Cambridge USA
| | | | - K. Stumpo
- Oncology Clinical Research; Takeda Pharmaceuticals; Cambridge USA
| | - Y. Shou
- Oncology Clinical Research; Takeda Pharmaceuticals International Co.; Cambridge USA
| | - C. Carpio
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - F. Bosch
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| |
Collapse
|
12
|
Casasnovas R, Westin J, Thieblemont C, Zijlstra J, Hill B, De La Cruz Vicente F, Choquet S, Caimi P, Kaplan J, Canales M, Kuruvilla J, Follows G, van den Neste E, Meade J, Wrigley B, Devlin M, Saint-Martin J, Nippgen C, Gardner H, Shacham S, Kauffman M, Maerevoet M. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - J. Westin
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - C. Thieblemont
- APHP, Hemato-Oncology; Hopital Saint-Louis; Paris France
| | - J. Zijlstra
- Lunenburg Lymphoma Phase-I Consortium; VU University Medical Center; Amsterdam The Netherlands
| | - B. Hill
- Taussig Cancer Institute; Cleveland Clinic; Cleveland USA
| | | | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - P. Caimi
- Seidman Cancer Center; University Hospital; Cleveland USA
| | - J. Kaplan
- Feinberg School of Medicine; Northwestern University; Chicago USA
| | - M. Canales
- Hematology; Hospital Universitario La Paz; Madrid Spain
| | - J. Kuruvilla
- Hematology; Princess Margaret Hospital; Toronto Canada
| | - G. Follows
- NHS Foundation Trust; Cambridge University Teaching Hospitals; Cambridge UK
| | - E. van den Neste
- Hematology; Cliniques Universitaires UCL Saint-Luc; Brussels Belgium
| | - J. Meade
- Clinical, Karyopharm Therapeutics; Newton USA
| | - B. Wrigley
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Devlin
- Clinical, Karyopharm Therapeutics; Newton USA
| | | | - C. Nippgen
- Clinical, Karyopharm Therapeutics; Newton USA
| | - H. Gardner
- Clinical, Karyopharm Therapeutics; Newton USA
| | - S. Shacham
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Kauffman
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Maerevoet
- Hematology; Institute Jules Bordet; Brussels Belgium
| |
Collapse
|
13
|
MacQueen BC, Christensen RD, Ward DM, Bennett ST, O’Brien EA, Sheffield MJ, Baer VL, Snow GL, Lewis KAW, Fleming RE, Kaplan J. The iron status at birth of neonates with risk factors for developing iron deficiency: a pilot study. J Perinatol 2017; 37:436-440. [PMID: 27977019 PMCID: PMC5389916 DOI: 10.1038/jp.2016.234] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 10/25/2016] [Accepted: 11/07/2016] [Indexed: 01/28/2023]
Abstract
OBJECTIVE Small-for-gestational-age (SGA) neonates, infants of diabetic mothers (IDM) and very-low-birth weight premature neonates (VLBW) are reported to have increased risk for developing iron deficiency and possibly associated neurocognitive delays. STUDY DESIGN We conducted a pilot study to assess iron status at birth in at-risk neonates by measuring iron parameters in umbilical cord blood from SGA, IDM, VLBW and comparison neonates. RESULTS Six of the 50 infants studied had biochemical evidence of iron deficiency at birth. Laboratory findings consistent with iron deficiency were found in one SGA, one IDM, three VLBW, and one comparison infant. None of the infants had evidence of iron deficiency anemia. CONCLUSIONS Evidence of biochemical iron deficiency at birth was found in 17% of screened neonates. Studies are needed to determine whether these infants are at risk for developing iron-limited erythropoiesis, iron deficiency anemia or iron-deficient neurocognitive delay.
Collapse
Affiliation(s)
- BC MacQueen
- Division of Neonatology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - RD Christensen
- Division of Neonatology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA,Women and Newborn’s Clinical Program, Intermountain Healthcare, Salt Lake City, UT, USA,Division of Hematology/Oncology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - DM Ward
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - ST Bennett
- Department of Pathology, Intermountain Medical Center, Murray, KY, USA
| | - EA O’Brien
- Division of Neonatology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA,Women and Newborn’s Clinical Program, Intermountain Healthcare, Salt Lake City, UT, USA
| | - MJ Sheffield
- Women and Newborn’s Clinical Program, Intermountain Healthcare, Salt Lake City, UT, USA
| | - VL Baer
- Women and Newborn’s Clinical Program, Intermountain Healthcare, Salt Lake City, UT, USA
| | - GL Snow
- Statistical Data Center, LDS Hospital, Salt Lake City, UT, USA
| | - KA Weaver Lewis
- Women and Newborn’s Clinical Program, Intermountain Healthcare, Salt Lake City, UT, USA
| | - RE Fleming
- Department of Pediatrics and Edward A. Doisy Department of Biochemistry and Molecular Biology, St Louis University, St Louis, MO, USA
| | - J Kaplan
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| |
Collapse
|
14
|
Stinson S, He J, Hollenback D, Jia J, Kaplan J, Venkataramani C, Babusis D, Guevara F, Nelson T, Cavanaugh J, Asahina H, Ray A, Sicinska E, Fuchs C, Barbie D, Wong K, Ng K, Dornan D. Anti-tumor activity of a TBK1/IKBKE inhibitor in combination with a MEK inhibitor in KRAS mutant colorectal and non-small cell lung cancer models. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)33033-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Lenaers G, Charif M, Amati-Bonneau P, Chao de la Barca J, Procaccio V, Gerber S, Kaplan J, Roubertie A, Meunier I, Reynier P, Rozet J, Hamel C, Bonneau D. The genetic pathophysiology of dominant optic atrophy. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Rozet J, Fares-Taïe L, Chassaing N, Gerber S, Kaplan J, Ragge N, Calvas P. Specific gene in microphthalmia. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Calvas P, Davis E, Ragge N, Fares-Taïe L, Srour M, Michaud J, Kaplan J, Rozet J, Chassaing N. Genetics in microphthalmia. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Perrault I, Halbritter J, Porath J, Gerard X, Braun D, Gee H, Fathy H, Saunier S, Cormier-Daire V, Thomas S, Attié-Bitach T, Boddaert N, Taschner M, Schueler M, Lorentzen E, Lifton R, Otto E, Bastin P, Kaplan J, Hildebrandt F, Rozet JM. Mutations of IFT81, encoding an IFT-B core protein, as a rare cause of a ciliopathy. Cilia 2015. [PMCID: PMC4519174 DOI: 10.1186/2046-2530-4-s1-p7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
19
|
Calvas P, Chassaing N, Kaplan J, Rozet J. Syndromic manifestations in aniridia patients with PAX6 point mutations. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - N. Chassaing
- Génétique Médicale; CHU & Université de Toulouse; Toulouse France
| | - J. Kaplan
- Institut Imagine- UMR1163 INSER-Univ Paris V; Laboratory of Ophthalmic Genetics; Paris France
| | - J.M. Rozet
- Institut IMAGINE- UMR1163 INSERM-Univ Paris V; Laboratory of Ophtalmic Genetics; Paris France
| |
Collapse
|
20
|
Kamm J, Bailey K, Kaplan J, McConnell J, Ardolf B, Jaramillo J, Westhafer J, Boyars L, Zartman A. NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS: TRAUMATIC BRAIN INJURYA-23Non-Neuropsychology Providers' Perception of Terminology, Recovery Time, and Treatment Needs in Mild Traumatic Brain Injury. Arch Clin Neuropsychol 2015. [DOI: 10.1093/arclin/acv047.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Kaplan J, Zartman A. B-17Performance on the Pillbox Test is Associated with a Neurocognitive Etiology. Arch Clin Neuropsychol 2015. [DOI: 10.1093/arclin/acv047.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Perrault I, Hanein S, Nicouleau M, Saunier S, Bole C, Nitschké P, Xerri O, Delphin N, Munnich A, Kaplan J, Rozet JM. Ciliome resequencing: A lifeline for molecular diagnosis in LCA. Cilia 2015. [PMCID: PMC4519145 DOI: 10.1186/2046-2530-4-s1-p55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
23
|
Patat O, van Ravenswaaij-Arts CMA, Tantau J, Corsten-Janssen N, van Tintelen JP, Dijkhuizen T, Kaplan J, Chassaing N. Otocephaly-Dysgnathia Complex: Description of Four Cases and Confirmation of the Role of OTX2. Mol Syndromol 2013; 4:302-5. [PMID: 24167467 DOI: 10.1159/000353727] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/22/2013] [Indexed: 11/19/2022] Open
Abstract
Otocephaly-dysgnathia complex is characterized by mandibular hypo- or aplasia, ear abnormalities, microstomia, and microglossia. Mutations in the orthodenticle homeobox 2 (OTX2) and paired related homeobox 1 (PRRX1) genes have recently been identified in some cases. We screened 4 otocephalic cases for these 2 genes and identified OTX2 mutations in 2 of them, thus confirming OTX2 is implicated in otocephaly. No PRRX1 mutation was identified. Interestingly, ocular involvement is not a constant feature in otocephalic cases with an OTX2 mutation. In one case, the mutation was inherited from a microphthalmic mother. The mechanism underlying this intrafamilial phenotypic variability remains unclear, but other genetic factors are likely to be necessary for the manifestation of the otocephalic phenotype.
Collapse
Affiliation(s)
- O Patat
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Kaplan J, Rozet JM, Gerber S, Camuzat A, Souïed E, Bonneau D, Larget-Piet D, Dollfus H, Dufier JL, Briard ML, Frézal J, Munnich A. Des gènes pour les dystrophies rétiniennes des enfants. Med Sci (Paris) 2013. [DOI: 10.4267/10608/2212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
25
|
Kaplan J. Cyril Jacob Kaplan. Assoc Med J 2012. [DOI: 10.1136/bmj.e7453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
|
27
|
Perrault I, Saunier S, Hanein S, Filhol E, Bizet A, Collins F, Salih M, Silva E, Baudouin V, Oud M, Shannon N, Le Merrer M, Pietrement C, Beales P, Arts H, Munnich A, Kaplan J, Antignac C, Cormier Daire V, Rozet JM. Mainzer-Saldino syndrome is a ciliopathy caused by mutations in the IFT140 gene. Cilia 2012. [PMCID: PMC3555764 DOI: 10.1186/2046-2530-1-s1-o28] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
28
|
Perrault I, Rozet JM, Munnich A, Kaplan J. Des mutations retrouvées pour la première fois dans une guanylyl cyclase (RetGC) responsables d'une cécité néo-natale : l'amaurose congénitale de Leber. ACTA ACUST UNITED AC 2012. [DOI: 10.4267/10608/416] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Turner M, Chretien N, Havari E, LaMorte M, Roberts B, Kaplan J, Siders W. Activity of an Anti-Murine CD52 Antibody in Experimental Autoimmune Encephalomyelitis (P05.117). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
30
|
Kaplan J. The stare of death. West J Med 2012. [DOI: 10.1136/bmj.d8283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Goldfarb SB, Dickler M, Patil S, Jia R, Sit L, Damast S, Carter J, Kaplan J, Hudis C, Basch E. PD04-03: Sexual Dysfunction in Premenopausal Women with Breast Cancer: Prevalence and Severity. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd04-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sexual dysfunction is reported after chemotherapy and endocrine therapies. However, the prevalence and severity of sexual dysfunction in premenopausal women undergoing therapy for both local and metastatic disease is not well defined. This study was performed in order to understand the impact of contemporary breast cancer treatment on the prevalence and severity of sexual health in premenopausal women.
Methods: We developed a survey that includes a previously validated questionnaire, the Female Sexual Function Index (FSFI), as well as an established measure of health-related quality of life (the EuroQol EQ-5D), and disease-specific items to characterize sexual dysfunction and its causes based on literature review and expert consultations. Anonymous administration of the surveys was conducted in outpatient clinic waiting areas of the Breast Cancer Center at Memorial Sloan-Kettering Cancer Center (MSKCC), under an IRB waiver of consent.
Results: 372 consecutively approached premenopausal women with breast cancer of any stage, undergoing treatment were each queried once. The mean age was 47. 87% reported current or past hormonal treatment, and 86% reported current or past chemotherapy (76% adjuvant; 24% for metastatic disease). Sexual dysfunction attributed to breast cancer or its treatment, defined as an FSFI score <26, was reported by 75% of respondents with a mean score of 16.3. Among these women, 79% of patients considered their sexual symptoms to be bothersome, with 51% noting moderate or severe levels of bother (score >=5/10). In a multivariate analysis, metastatic disease, development of amenorrhea from cancer treatment, antidepressant use and poorer overall health were each significantly associated with worse FSFI scores. Lower FSFI scores were also significantly associated with worse health-related quality of life.
Conclusion: Sexual dysfunction is prevalent in premenopausal women treated for breast cancer and should be discussed with patients as a potential adverse effect of therapy. Assessment of sexual symptoms throughout treatment and beyond may facilitate the use of potential interventions such as lubricants, dilators, treatment modification and counseling.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD04-03.
Collapse
Affiliation(s)
- SB Goldfarb
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M Dickler
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S Patil
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R Jia
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L Sit
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S Damast
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J Carter
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J Kaplan
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C Hudis
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| | - E Basch
- 1Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
32
|
Kaplan J, Kaplan FS, Shore EM. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther 2011; 19:786-90. [PMID: 22011642 DOI: 10.1038/gt.2011.152] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of progressive heterotopic ossification for which there is presently no cure. FOP is caused by a recurrent heterozygous activating mutation (c.617G>A; R206H) of Activin receptor type IA/Activin-like kinase-2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor that occurs in all classically affected individuals. The FOP mutation dysregulates BMP signaling and initiates the formation of a disabling second skeleton of heterotopic bone. We generated allele-specific siRNA (ASP-RNAi) duplexes capable of specifically suppressing the expression of the mutant c.617A allele in mesenchymal progenitor cells from FOP patients and showed that this ASP-RNAi approach decreased the elevated BMP signaling that is characteristic of patient cells to levels similar to control cells and restored enhanced osteogenic differentiation to control levels. Our results provide proof-of-principle that ASP-RNAi has potential therapeutic efficacy for the treatment of FOP.
Collapse
Affiliation(s)
- J Kaplan
- Department of Orthopaedic Surgery, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
| | | | | |
Collapse
|
33
|
Chacón M, Vilchez V, Angel M, Arganaraz F, Kaplan J, Chacón R. 9432 POSTER Age, Location and Histology in Soft Tissue Sarcomas – Single Institutional Review. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72576-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
34
|
Kaplan J, Han L, Halgrimson W, Wang E, Fryer J. The impact of MELD/PELD revisions on the mortality of liver-intestine transplantation candidates. Am J Transplant 2011; 11:1896-904. [PMID: 21827611 DOI: 10.1111/j.1600-6143.2011.03628.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Patients listed for liver-intestine transplantation suffer higher waiting list mortality than those listed for liver-only, thus leading to policy revisions seeking to close the gap. We sought to determine the impact of key model for end-stage liver disease (MELD)/pediatric end-stage liver disease (PELD) policy modifications on the waiting list mortality of adult and pediatric liver-intestine candidates as compared to liver-only candidates. Analysis of UNOS data separated into adult and pediatric categories and based on time periods of policy implementation revealed higher mortality in liver-intestine candidates over all time periods studied (p < 0.001 pediatric and adult). After implementation of a revision to augment their MELD scores based on a sliding scale, adult liver-intestine candidates with calculated MELD > 15 no longer suffered higher mortality although this change did not completely eliminate the mortality disparity for candidates with MELD < 15 (p < 0.01). The waiting list mortality of pediatric liver-intestine candidates dropped significantly after a revision that gave them 23 additional MELD/PELD points (p < 0.01) although the mortality disparity with pediatric liver-only candidates was not eliminated. Following this revision, mortality in pediatric liver-only and liver-intestine Status 1 candidates was similar, however more liver-intestine candidates were listed as Status 1B. This data demonstrates that a mortality disparity remains for liver-intestine candidates compared with candidates listed for liver-only.
Collapse
Affiliation(s)
- J Kaplan
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | | | | | | | | |
Collapse
|
35
|
Saulnier Sholler GL, Eslin D, Roberts WD, Kaplan J, Bergendahl G, Ashikaga T, Higgins T, Lenox S, Silberman S, Ferguson W. Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Goldfarb SB, Kelvin JF, Thom B, Kaplan J, Margolies A, Corcoran S, McCabe MS, Hudis C, Basch EM, Dickler MN. Fertility preservation: Are we telling patients what they want to know? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Goldfarb SB, Kelvin JF, Thom B, Kaplan J, Corcoran S, Margolies A, McCabe MS, Norton L, Hudis C, Basch E, Dickler MN. Abstract P2-14-08: Patient Perspectives on Information Communicated Regarding Effects of Treatment on Fertility. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many breast cancer survivors diagnosed during their reproductive years desire to have children after treatment and are distressed about the possibility of treatment-induced infertility. Informing patients about fertility preservation options before therapy may optimize quality of life after treatment. This study was undertaken to evaluate the information patients received about effects of therapy on fertility, early menopause, and fertility preservation options. Methods:
An IRB approved cross-sectional study was performed to evaluate patient perceptions of the impact of treatment on fertility and early menopause. The survey was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) for patients ages 18-45, with items derived from existing surveys in the literature and input from a multidisciplinary committee. We evaluated two groups of patients, one who had completed treatment and the other who was currently undergoing therapy. Surveys were mailed to 395 women who began treatment (all modalities) for breast cancer at MSKCC between 7/1/07 and 6/30/08. A second cohort of patients (n=35) completed surveys during patient visits to breast cancer medicine ambulatory clinics
between 3/22/2010 and 4/8/2010.
Results:
The survey was completed by 159 pts. (129/395 and 30/35). At the time of diagnosis, 69% (110/159) had children and 45% (70/156) were interested in having children. 79% (123/155) reported that the impact of treatment on fertility was discussed with them before initiating therapy. A healthcare provider initiated the discussion 54% (83/155) of the time. However, only 35% (54/152) and 47% (71/150) of women felt they received an adequate amount of information about the effect of cancer treatment on fertility and menopause, respectively. Based on their ranking, patients preferred to receive fertility information in person either from their physician or a fertility specialist, or through written material. After treatment, 5 patients attempted pregnancy (7 naturally, 1 with assisted technology), yielding 8 live births. Conclusions:
Many breast cancer survivors wish to have children after treatment. To optimize success, patients should be adequately informed about the effects of therapy on fertility, early menopause, and options for fertility preservation. These findings are informing an institution-wide fertility program.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-14-08.
Collapse
Affiliation(s)
- SB Goldfarb
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - JF Kelvin
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B Thom
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J Kaplan
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S Corcoran
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A Margolies
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - MS McCabe
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L Norton
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - E Basch
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - MN. Dickler
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
38
|
Kaplan J. The danger of do-gooders. West J Med 2010. [DOI: 10.1136/bmj.c4585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Papon JF, Perrault I, Coste A, Louis B, Gérard X, Hanein S, Fares-Taie L, Gerber S, Defoort-Dhellemmes S, Vojtek AM, Kaplan J, Rozet JM, Escudier E. Abnormal respiratory cilia in non-syndromic Leber congenital amaurosis with CEP290 mutations. J Med Genet 2010; 47:829-34. [PMID: 20805370 DOI: 10.1136/jmg.2010.077883] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Leber congenital amaurosis (LCA) is the earliest and most severe inherited retinal degeneration. Isolated forms of LCA frequently result from mutation of the CEP290 gene which is expressed in various ciliated tissues. METHODS Seven LCA patients with CEP290 mutations were investigated to study otorhinolaryngologic phenotype and respiratory cilia. Nasal biopsies and brushing were performed to study cilia ultrastructure using transmission electron microscopy and ciliary beating using high-speed videomicroscopy, respectively. CEP290 expression in normal nasal epithelium was studied using real-time RT-PCR. RESULTS When electron microscopy was feasible (5/7), high levels of respiratory cilia defects were detected. The main defects concerned dynein arms, central complex and/or peripheral microtubules. All patients had a rarefaction of ciliated cells and a variable proportion of short cilia. Frequent but moderate and heterogeneous clinical and ciliary beating abnormalities were found. CEP290 was highly expressed in the neural retina and nasal epithelial cells compared with other tissues. DISCUSSION These data provide the first clear demonstration of respiratory cilia ultrastructural defects in LCA patients with CEP290 mutations. The frequency of these findings in LCA patients along with the high expression of CEP290 in nasal epithelium suggest that CEP290 has an important role in the proper development of both the respiratory ciliary structures and the connecting cilia of photoreceptors. The presence of respiratory symptoms in patients could represent additional clinical criteria to direct CEP290 genotyping of patients affected with the genetically heterogeneous cone-rod dystrophy subtype of LCA.
Collapse
|
40
|
Kumar R, Iachini DN, Neilsen PM, Kaplan J, Michalakas J, Anderson PH, May BK, Morris HA, Callen DF. Systematic characterisation of the rat and human CYP24A1 promoter. Mol Cell Endocrinol 2010; 325:46-53. [PMID: 20450955 DOI: 10.1016/j.mce.2010.04.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2009] [Revised: 03/22/2010] [Accepted: 04/27/2010] [Indexed: 10/19/2022]
Abstract
The biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) ligands VDR (vitamin D receptor) and binds to the vitamin D response element (VDRE) located within target genes to regulate their transcription. Previously we showed that 1,25D-mediated rat CYP24A1 induction via the two critical VDREs is dependent on a short stretch of nucleotides called vitamin D stimulating element (VSE), located approximately 30bp upstream of VDRE-1 in the rat CYP24A1 promoter. We have now undertaken systematic analysis of the human CYP24A1 and rat CYP24A1 promoters to determine if the VSE is present in the human promoter. Using electrophoretic mobility shift and dual-luciferase reporter assays, we show that the VSE is absent in the human CYP24A1 promoter. In addition, we show that 1,25D-mediated induction of human CYP24A1 is dependant upon a promoter region spanning nucleotides -470 to -392 of the human CYP24A1 promoter.
Collapse
Affiliation(s)
- R Kumar
- Breast Cancer Genetics Group, Discipline of Medicine, University of Adelaide and Hanson Institute, SA Pathology, Frome Road, Adelaide, SA 5000, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Rio M, Lebre AS, de Lonlay P, Valayannopoulos V, Desguerre I, Dufier JL, Grévent D, Zilbovicius M, Tréguier C, Brunelle F, de Baracé C, Kaplan J, Espinase-Berrod MA, Sainte-Rose C, Puget S, Rotig A, Munnich A, Boddaert N. Mitochondrial ND5 mutations mimicking brainstem tectal glioma. Neurology 2010; 75:93. [PMID: 20603491 DOI: 10.1212/wnl.0b013e3181e6214a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- M Rio
- Département de Génétique, Tour Lavoisier 2 étage, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
A method of systematic task analysis is applied to the problem of designing a sequence of learning objectives that will provide an optimal match for the child's natural sequence of acquisition of mathematical skills and concepts. The authors begin by proposing an operational definition of the number concept in the form of a set of behaviors which, taken together, permit the inference that the child has an abstract concept of "number". These are the "objectives" of the curriculum. Each behavior in the defining set is then subjected to an analysis that identifies hypothesized components of skilled performance and prerequisites for learning these components. On the basis of these analyses, specific sequences of learning objectives are proposed. The proposed sequences are hypothesized to be those that will best facilitate learning, by maximizing transfer from earlier to later objectives. Relevant literature on early learning and cognitive development is considered in conjunction with the analyses and the resulting sequences. The paper concludes with a discussion of the ways in which the curriculum can be implemented and studied in schools. Examples of data on individual children are presented, and the use of such data for improving the curriculum itself, as well as for examining the effects of other treatment variables, is considered.
Collapse
|
43
|
Kaplan J. In the line of fire. West J Med 2010. [DOI: 10.1136/bmj.c2967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Saulnier Sholler GL, Bergendahl G, Lenox S, Zage PE, Roberts W, Kraveka JM, Eslin D, Kaplan J, Higgins T, Ferguson W. A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Youd M, Blickarz C, Woodworth L, Touzjian T, Edling A, Tedstone J, Ruzek M, Tubo R, Kaplan J, Lodie T. Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 2010; 161:176-86. [PMID: 20456409 DOI: 10.1111/j.1365-2249.2010.04158.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Mesenchymal stem cell (MSC) therapy has shown promise clinically in graft-versus-host disease and in preclinical animal models of T helper type 1 (Th1)-driven autoimmune diseases, but whether MSCs can be used to treat autoimmune disease in general is unclear. Here, the therapeutic potential of MSCs was tested in the New Zealand black (NZB)xNew Zealand white (NZW) F1 (NZB/W) lupus mouse model. The pathogenesis of systemic lupus erythematosus involves abnormal B and T cell activation leading to autoantibody formation. To test whether the immunomodulatory activity of MSCs would inhibit the development of autoimmune responses and provide a therapeutic benefit, NZB/W mice were treated with Balb/c-derived allogeneic MSCs starting before or after disease onset. Systemic MSC administration worsened disease and enhanced anti-double-stranded DNA (dsDNA) autoantibody production. The increase in autoantibody titres was accompanied by an increase in plasma cells in the bone marrow, an increase in glomerular immune complex deposition, more severe kidney pathology, and greater proteinuria. Co-culturing MSCs with plasma cells purified from NZB/W mice led to an increase in immunoglobulin G antibody production, suggesting that MSCs might be augmenting plasma cell survival and function in MSC-treated animals. Our results suggest that MSC therapy may not be beneficial in Th2-type T cell- and B cell-driven diseases such as lupus and highlight the need to understand further the appropriate application of MSC therapy.
Collapse
Affiliation(s)
- M Youd
- Stem Cell Biology, Genzyme Corporation, Framingham, MA 01701, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Muller J, Stoetzel C, Vincent MC, Leitch CC, Laurier V, Danse JM, Hellé S, Marion V, Bennouna-Greene V, Vicaire S, Megarbane A, Kaplan J, Drouin-Garraud V, Hamdani M, Sigaudy S, Francannet C, Roume J, Bitoun P, Goldenberg A, Philip N, Odent S, Green J, Cossée M, Davis EE, Katsanis N, Bonneau D, Verloes A, Poch O, Mandel JL, Dollfus H. Identification of 28 novel mutations in the Bardet-Biedl syndrome genes: the burden of private mutations in an extensively heterogeneous disease. Hum Genet 2010; 127:583-93. [PMID: 20177705 DOI: 10.1007/s00439-010-0804-9] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2009] [Accepted: 02/10/2010] [Indexed: 12/01/2022]
Abstract
Bardet-Biedl syndrome (BBS), an emblematic disease in the rapidly evolving field of ciliopathies, is characterized by pleiotropic clinical features and extensive genetic heterogeneity. To date, 14 BBS genes have been identified, 3 of which have been found mutated only in a single BBS family each (BBS11/TRIM32, BBS13/MKS1 and BBS14/MKS4/NPHP6). Previous reports of systematic mutation detection in large cohorts of BBS families (n > 90) have dealt only with a single gene, or at most small subsets of the known BBS genes. Here we report extensive analysis of a cohort of 174 BBS families for 12/14 genes, leading to the identification of 28 novel mutations. Two pathogenic mutations in a single gene have been found in 117 families, and a single heterozygous mutation in 17 families (of which 8 involve the BBS1 recurrent mutation, M390R). We confirm that BBS1 and BBS10 are the most frequently mutated genes, followed by BBS12. No mutations have been found in BBS11/TRIM32, the identification of which as a BBS gene only relies on a single missense mutation in a single consanguineous family. While a third variant allele has been observed in a few families, they are in most cases missenses of uncertain pathogenicity, contrasting with the type of mutations observed as two alleles in a single gene. We discuss the various strategies for diagnostic mutation detection, including homozygosity mapping and targeted arrays for the detection of previously reported mutations.
Collapse
Affiliation(s)
- Jean Muller
- Laboratoire de Diagnostic Génétique, CHU Strasbourg Nouvel Hôpital Civil, 1 place de l'Hôpital, 67000 Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Aboussair N, Berahou A, Perrault I, Elalaoui SC, Megzari A, Rozet JM, Kaplan J, Sefiani A. [First North African observation of Leber congenital amaurosis secondary to CEP290 gene mutation]. J Fr Ophtalmol 2010; 33:117.e1-5. [PMID: 20056295 DOI: 10.1016/j.jfo.2009.11.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2009] [Accepted: 04/13/2009] [Indexed: 01/24/2023]
Abstract
Leber congenital amaurosis (LCA) is a the earliest and most severe form of retinal dystrophy responsible for congenital blindness. LCA has genetic heterogeneity and the study of this disease is elucidating the genetics and molecular interactions involved in the development of the retina. To date, 11 LCA genes have been mapped, ten of which have been identified. The CEP290 gene has been shown to account for Joubert and Senior-Loken syndromes and to be a frequent cause of nonsyndromic LCA. We report here the first Arab patient, born to consanguineous parents, with Leber congenital amaurosis attributable to mutation of the CEP290 gene.
Collapse
Affiliation(s)
- N Aboussair
- Département de Génétique Médicale, Institut National d'Hygiène, Rabat, Maroc.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Kaplan J, Kaplan J, Schnitt S, Schnitt S, Collins L, Collins L, Wang Y, Wang Y, Garber J, Garber J, Tung N, Tung N. Estrogen Rececptor (ER)-Positive Breast Cancers in BRCA1 Mutation Carriers: Mutation-Related or Sporadic? Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Most invasive breast cancers (IBC) in BRCA1 mutation carriers are ER negative (-) and have a basal-like phenotype by expression array analysis. These tumors also have a characteristic constellation of histologic features including high grade, high mitotic rate, prominent lymphoid infiltrate, circumscribed or pushing margins, and geographic necrosis or a central fibrotic focus and typically lack ER, PR and HER2 expression (triple negative). ER positive (+) breast cancers also occur in women with germline BRCA1 mutations, but these tumors are less frequent and less well characterized. We previously reported that ER+ BRCA1-associated IBC show a wider spectrum of histologic types and grades than ER- cancers that occur in these patients. We raised the possibility that at least some ER+ BRCA1-associated IBC may be sporadic rather than mutation-related. However, it is not known how the features of these ER+ BRCA1-associated IBC compare with those of sporadic ER+ IBC.Design: To address this issue, we performed a case-control study of 60 ER+ BRCA1-associated IBC (cases) matched on age and year of diagnosis with 174 ER+ sporadic breast cancers (controls). Histologic sections of cases and controls were reviewed and the pathologic features were compared with each other as well with those of 85 ER- IBC that developed in BRCA1 mutation carriers.Results: Histologic features are summarized in the Table. When compared with ER+ controls, ER+ BRCA1-associated IBC were significantly more likely to be invasive ductal carcinomas (78% vs 58%;p=0.005), histologic grade 3 (47% vs 27%;p=0.006), and to have a high mitotic rate (29% vs 9%;p=0.0003). However, all of these features were significantly less frequent in ER+ BRCA1-associated IBC than in ER- BRCA1-associated IBC (p<0.001 for all comparisons). ER+ BRCA1-associated IBC and ER+ controls were not significantly different from each other with regard to the frequency of moderate-severe lymphoid infiltrate, the presence of geographic necrosis or the presence of a fibrotic focus, but the frequency of all of these features in both groups was significantly lower than in ER- BRCA1-associated IBC (p<0.01 for all comparisons). ER+ ControlsER+ BRCA1ER- BRCA1 N=174N=60N=85Histologic Type Invasive Ductal58%78%96%Other42%22%4%Histologic Grade 327%47%96%1 or 273%53%4%Mitotic Rate ≥10/10 HPF9%29%93%<10/10 HPF91%71%7%Tumor Margin Invasive96%90%37%Pushing/Circumscribed4%10%63%Lymphoid Infiltrate Moderate-Severe16%7%30%Other84%93%70%Fibrotic Focus Present7%12%56%Absent93%88%44%Geographic Necrosis Present2%5%50%Absent98%95%50% Conclusions: ER+ breast cancers arising in women with BRCA1 germline mutations appear to be pathologically "intermediate" between ER- BRCA1-associated breast cancers and ER+ sporadic breast cancers. This raises the possibility that some ER+ BRCA1-associated invasive breast cancers are mutation-related and others are sporadic or that there is a unique mechanism by which ER+ cancers develop in mutation carriers. Immunophenotypic and molecular studies are in progress to further characterize this interesting group of tumors.This work was supported by a grant from the Breast Cancer Research Foundation.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5162.
Collapse
Affiliation(s)
- J. Kaplan
- 1Beth Israel Deaconess Medical Center, MA,
| | | | - S. Schnitt
- 1Beth Israel Deaconess Medical Center, MA,
| | | | - L. Collins
- 1Beth Israel Deaconess Medical Center, MA,
| | | | - Y. Wang
- 1Beth Israel Deaconess Medical Center, MA,
| | - Y. Wang
- 2Harvard Medical School, MA,
| | | | | | - N. Tung
- 1Beth Israel Deaconess Medical Center, MA,
| | - N. Tung
- 2Harvard Medical School, MA,
| |
Collapse
|
49
|
Goldfarb S, Dickler M, Fruscione M, Sit L, Jia R, Kaplan J, Barz T, Atkinson T, Hudis C, Basch E. Burden of Sexual Dysfunction in Women with Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-1056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sexual dysfunction is reported after chemotherapy and endocrine therapies, and causes a substantial burden on women with breast cancer. However, the prevalence and severity of sexual dysfunction in women undergoing therapy for both local and metastatic disease is not well defined. Improved understanding of sexual dysfunction may facilitate enhanced treatment and interventions in patients with breast cancer undergoing active treatment, and in survivors of this disease.Methods: We developed a survey that includes a previously validated questionnaire, the female sexual function index (FSFI), as well as an established measure of health-related quality of life (the EuroQol EQ-5D), and disease-specific items to characterize sexual dysfunction and its causes based on literature review and expert consultations. Anonymous administration of the surveys was conducted in outpatient clinic waiting areas of the Breast Cancer Center at Memorial Sloan-Kettering Cancer Center (MSKCC) and two community centers, under an IRB waiver of consent.Results: During November 2008 through May 2009, 509 women undergoing treatment for breast cancer of all stages were each queried once. The mean age was 51 (range 26-91). 87% reported current or past hormonal treatment, and 82% reported current or past chemotherapy (76% adjuvant; 24% for metastatic disease). Sexual dysfunction attributed to breast cancer or its treatment, defined as an FSFI score <26, was reported by 76% of respondents. Among these women, 316/386 (82%) patients considered their sexual symptoms to be bothersome, with 247/386 (64%) noting moderate or severe levels of bother (score >=5/10). Patients attributed their sexual dysfunction to chemotherapy in 318/373 (85%) of cases; to hormonal therapy in 221/298 (74%) of cases; and to surgery in 331/442 (66%) of cases. Other reported contributors to sexual dysfunction include a new diagnosis of breast cancer by 81% of respondents, anxiety by 82% of respondents, and change in relationship with a partner by 55% of respondents.Conclusion: Sexual dysfunction is prevalent in women treated for breast cancer and should be discussed with patients as a potential adverse effect of therapy. Assessment of sexual symptoms throughout treatment and beyond may facilitate the use of potential interventions such as lubricants, dilators, treatment modification, topical estrogens, and counseling. Future work includes a longitudinal prospective trial to further characterize the etiologies of these symptoms and a randomized controlled trial to evaluate interventions for sexual dysfunction.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1056.
Collapse
Affiliation(s)
- S. Goldfarb
- 1Memorial Sloan-Kettering Cancer Center, NY,
| | - M. Dickler
- 2Memorial Sloan-Kettering Cancer Center, NY,
| | | | - L. Sit
- 3Memorial Sloan-Kettering Cancer Center, NY,
| | - R. Jia
- 4Memorial Sloan-Kettering Cancer Center, NY,
| | - J. Kaplan
- 3Memorial Sloan-Kettering Cancer Center, NY,
| | - T. Barz
- 3Memorial Sloan-Kettering Cancer Center, NY,
| | - T. Atkinson
- 3Memorial Sloan-Kettering Cancer Center, NY,
| | - C. Hudis
- 2Memorial Sloan-Kettering Cancer Center, NY,
| | - E. Basch
- 5Memorial Sloan-Kettering Cancer Center, NY,
| |
Collapse
|
50
|
Dassie-Ajdid J, Causse A, Poidvin A, Granier M, Kaplan J, Burglen L, Doummar D, Teisseire P, Vigouroux A, Malecaze F, Calvas P, Chassaing N. NovelB3GALTLmutation in Peters-plus Syndrome. Clin Genet 2009; 76:490-2. [DOI: 10.1111/j.1399-0004.2009.01253.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|